Your browser doesn't support javascript.
loading
Discovery of AZD4747, a Potent and Selective Inhibitor of Mutant GTPase KRASG12C with Demonstrable CNS Penetration.
Kettle, Jason G; Bagal, Sharan K; Barratt, Derek; Bodnarchuk, Michael S; Boyd, Scott; Braybrooke, Erin; Breed, Jason; Cassar, Doyle J; Cosulich, Sabina; Davies, Michael; Davies, Nichola L; Deng, Chao; Eatherton, Andrew; Evans, Laura; Feron, Lyman J; Fillery, Shaun; Gleave, Emma S; Goldberg, Frederick W; Cortés González, Miguel A; Guerot, Carine; Haider, Afreen; Harlfinger, Stephanie; Howells, Rachel; Jackson, Anne; Johnström, Peter; Kemmitt, Paul D; Koers, Alex; Kondrashov, Mikhail; Lamont, Gillian M; Lamont, Scott; Lewis, Hilary J; Liu, Libin; Mylrea, Megan; Nash, Samuel; Niedbala, Michael J; Peter, Alison; Phillips, Christopher; Pike, Kurt; Raubo, Piotr; Robb, Graeme R; Ross, Sarah; Sanders, Matthew G; Schou, Magnus; Simpson, Iain; Steward, Oliver.
Afiliação
  • Kettle JG; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Bagal SK; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Barratt D; Discovery Sciences, R&D, AstraZeneca,, Cambridge CB4 0WG, U.K.
  • Bodnarchuk MS; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Boyd S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Braybrooke E; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Breed J; Discovery Sciences, R&D, AstraZeneca,, Cambridge CB4 0WG, U.K.
  • Cassar DJ; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Cosulich S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Davies M; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Davies NL; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Deng C; Pharmaron Beijing Co., Ltd. 6 Taihe Road BDA, Beijing 100176, P. R. China.
  • Eatherton A; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Evans L; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Feron LJ; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Fillery S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Gleave ES; Discovery Sciences, R&D, AstraZeneca,, Cambridge CB4 0WG, U.K.
  • Goldberg FW; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Cortés González MA; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm SE-171 76, Sweden.
  • Guerot C; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Haider A; Discovery Sciences, R&D, AstraZeneca,, Cambridge CB4 0WG, U.K.
  • Harlfinger S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Howells R; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Jackson A; Discovery Sciences, R&D, AstraZeneca,, Cambridge CB4 0WG, U.K.
  • Johnström P; PET Science Centre, Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Karolinska Institutet, Stockholm SE-171 76, Sweden.
  • Kemmitt PD; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm SE-171 76, Sweden.
  • Koers A; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Kondrashov M; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Lamont GM; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm SE-171 76, Sweden.
  • Lamont S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Lewis HJ; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Liu L; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Mylrea M; Pharmaron Beijing Co., Ltd. 6 Taihe Road BDA, Beijing 100176, P. R. China.
  • Nash S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Niedbala MJ; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Peter A; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States.
  • Phillips C; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Pike K; Discovery Sciences, R&D, AstraZeneca,, Cambridge CB4 0WG, U.K.
  • Raubo P; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Robb GR; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Ross S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Sanders MG; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Schou M; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Simpson I; PET Science Centre, Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Karolinska Institutet, Stockholm SE-171 76, Sweden.
  • Steward O; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm SE-171 76, Sweden.
J Med Chem ; 66(13): 9147-9160, 2023 07 13.
Article em En | MEDLINE | ID: mdl-37395055
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pulmonares / Neoplasias / Antineoplásicos Limite: Animals / Humans Idioma: En Revista: J Med Chem Assunto da revista: QUIMICA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pulmonares / Neoplasias / Antineoplásicos Limite: Animals / Humans Idioma: En Revista: J Med Chem Assunto da revista: QUIMICA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido